Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas - PubMed (original) (raw)
. 2012 Jan 29;44(3):251-3.
doi: 10.1038/ng.1102.
Alberto Broniscer, Troy A McEachron, Charles Lu, Barbara S Paugh, Jared Becksfort, Chunxu Qu, Li Ding, Robert Huether, Matthew Parker, Junyuan Zhang, Amar Gajjar, Michael A Dyer, Charles G Mullighan, Richard J Gilbertson, Elaine R Mardis, Richard K Wilson, James R Downing, David W Ellison, Jinghui Zhang, Suzanne J Baker; St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project
Affiliations
- PMID: 22286216
- PMCID: PMC3288377
- DOI: 10.1038/ng.1102
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
Gang Wu et al. Nat Genet. 2012.
Abstract
To identify somatic mutations in pediatric diffuse intrinsic pontine glioma (DIPG), we performed whole-genome sequencing of DNA from seven DIPGs and matched germline tissue and targeted sequencing of an additional 43 DIPGs and 36 non-brainstem pediatric glioblastomas (non-BS-PGs). We found that 78% of DIPGs and 22% of non-BS-PGs contained a mutation in H3F3A, encoding histone H3.3, or in the related HIST1H3B, encoding histone H3.1, that caused a p.Lys27Met amino acid substitution in each protein. An additional 14% of non-BS-PGs had somatic mutations in H3F3A causing a p.Gly34Arg alteration.
Conflict of interest statement
The authors have no competing financial interests.
Figures
Figure 1. Recurrent somatic mutations in H3F3A and HIST1H3B
Sanger sequencing chromatograms showing representative H3F3A or HIST1H3B mutations encoding p.K27M substitutions, or H3F3A mutation encoding p.G34R substitution in the indicated tumour compared to matched normal DNA. Arrow indicates mutation. SJHGG001 and SJHGG079 are DIPGs, SJHGG043 is a non-brainstem paediatric glioblastoma.
Comment in
- Cancer genomics: Histone modification at the gene level.
Burgess DJ. Burgess DJ. Nat Rev Genet. 2012 Feb 14;13(3):148-9. doi: 10.1038/nrg3181. Nat Rev Genet. 2012. PMID: 22330763 No abstract available. - Histone modification at the gene level.
Burgess DJ. Burgess DJ. Nat Rev Cancer. 2012 Feb 24;12(3):156. doi: 10.1038/nrc3233. Nat Rev Cancer. 2012. PMID: 22362212 No abstract available.
Similar articles
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, Bourgey M, Bourque G, Montpetit A, Bourret G, Lepage P, Fleming A, Lichter P, Kool M, von Deimling A, Sturm D, Korshunov A, Faury D, Jones DT, Majewski J, Pfister SM, Jabado N, Hawkins C. Khuong-Quang DA, et al. Acta Neuropathol. 2012 Sep;124(3):439-47. doi: 10.1007/s00401-012-0998-0. Epub 2012 Jun 3. Acta Neuropathol. 2012. PMID: 22661320 Free PMC article. - Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pagès M, Taylor KR, Saulnier P, Lacroix L, Mackay A, Jones C, Sainte-Rose C, Blauwblomme T, Andreiuolo F, Puget S, Grill J, Varlet P, Debily MA. Castel D, et al. Acta Neuropathol. 2015 Dec;130(6):815-27. doi: 10.1007/s00401-015-1478-0. Epub 2015 Sep 23. Acta Neuropathol. 2015. PMID: 26399631 Free PMC article. - Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, Spratt DE, Leonard M, Qin T, Zhao L, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C. Gits HC, et al. Acta Neuropathol Commun. 2018 Jul 26;6(1):67. doi: 10.1186/s40478-018-0570-9. Acta Neuropathol Commun. 2018. PMID: 30049282 Free PMC article. - Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
Mendez FM, Núñez FJ, Garcia-Fabiani MB, Haase S, Carney S, Gauss JC, Becher OJ, Lowenstein PR, Castro MG. Mendez FM, et al. Neuro Oncol. 2020 Feb 20;22(2):195-206. doi: 10.1093/neuonc/noz218. Neuro Oncol. 2020. PMID: 32078691 Free PMC article. Review. - Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape.
Panditharatna E, Yaeger K, Kilburn LB, Packer RJ, Nazarian J. Panditharatna E, et al. Cancer Genet. 2015 Jul-Aug;208(7-8):367-73. doi: 10.1016/j.cancergen.2015.04.008. Epub 2015 May 1. Cancer Genet. 2015. PMID: 26206682 Review.
Cited by
- Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases.
Yao W, Hu X, Wang X. Yao W, et al. Signal Transduct Target Ther. 2024 Sep 16;9(1):232. doi: 10.1038/s41392-024-01918-w. Signal Transduct Target Ther. 2024. PMID: 39278916 Free PMC article. Review. - Roles of Histone H2B, H3 and H4 Variants in Cancer Development and Prognosis.
Lai PM, Gong X, Chan KM. Lai PM, et al. Int J Mol Sci. 2024 Sep 7;25(17):9699. doi: 10.3390/ijms25179699. Int J Mol Sci. 2024. PMID: 39273649 Free PMC article. Review. - Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance.
Stegat L, Eckhardt A, Gocke A, Neyazi S, Pohl L, Schmid S, Dottermusch M, Frank S, Pinnschmidt H, Herms J, Glatzel M, Snuderl M, Schweizer L, Thomas C, Neumann J, Dorostkar MM, Schüller U, Wefers AK. Stegat L, et al. Acta Neuropathol. 2024 Sep 10;148(1):40. doi: 10.1007/s00401-024-02800-3. Acta Neuropathol. 2024. PMID: 39256213 Free PMC article. - Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function.
Andrade AF, Annett A, Karimi E, Topouza DG, Rezanejad M, Liu Y, McNicholas M, Gonzalez Santiago EG, Llivichuzhca-Loja D, Gehlhaar A, Jessa S, De Cola A, Chandarana B, Russo C, Faury D, Danieau G, Puligandla E, Wei Y, Zeinieh M, Wu Q, Hebert S, Juretic N, Nakada EM, Krug B, Larouche V, Weil AG, Dudley RWR, Karamchandani J, Agnihotri S, Quail DF, Ellezam B, Konnikova L, Walsh LA, Pathania M, Kleinman CL, Jabado N. Andrade AF, et al. Nat Commun. 2024 Sep 5;15(1):7769. doi: 10.1038/s41467-024-52096-w. Nat Commun. 2024. PMID: 39237515 Free PMC article. - Histone H3.3 lysine 9 and 27 control repressive chromatin at cryptic enhancers and bivalent promoters.
Trovato M, Bunina D, Yildiz U, Fernandez-Novel Marx N, Uckelmann M, Levina V, Perez Y, Janeva A, Garcia BA, Davidovich C, Zaugg JB, Noh KM. Trovato M, et al. Nat Commun. 2024 Aug 30;15(1):7557. doi: 10.1038/s41467-024-51785-w. Nat Commun. 2024. PMID: 39214979 Free PMC article.
References
- Broniscer A, Gajjar A. The oncologist. 2004;9:197–206. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA129541/CA/NCI NIH HHS/United States
- P01 CA096832-08/CA/NCI NIH HHS/United States
- R01 CA135554/CA/NCI NIH HHS/United States
- CA096832/CA/NCI NIH HHS/United States
- R01 CA135554-09/CA/NCI NIH HHS/United States
- P01 CA096832/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases